collection
MENU ▼
Read by QxMD icon Read
search

Rheumatoid arthritis

shared collection
121 papers 25 to 100 followers
https://www.readbyqxmd.com/read/29884751/ability-of-disease-modifying-antirheumatic-drugs-to-prevent-or-delay-rheumatoid-arthritis-onset-a-systematic-literature-review-and-meta-analysis
#1
REVIEW
Stéphane Hilliquin, Benjamin Hugues, Stéphane Mitrovic, Laure Gossec, Bruno Fautrel
BACKGROUND: Recent advances in knowledge of the pathogenesis of rheumatoid arthritis (RA) has led to promoting very early intervention. OBJECTIVES: To assess the efficacy of therapeutic interventions in preventing or delaying RA onset with a systematic literature review (SLR) and meta-analysis (MA). METHODS: The SLR aimed to include all reports of randomised controlled trials of disease-modifying antirheumatic drugs or glucocorticoids used in patients presenting genetic and/or environmental risk factors for RA and/or systemic autoimmunity associated with RA, and/or symptoms without clinical arthritis and/or unclassified arthritis and in patients with RA...
June 8, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29416134/the-b-cell-response-to-citrullinated-antigens-in-the-development-of-rheumatoid-arthritis
#2
REVIEW
Hans Ulrich Scherer, Tom W J Huizinga, Gerhard Krönke, Georg Schett, Rene E M Toes
The immune response to citrullinated antigens is found almost exclusively in patients with rheumatoid arthritis (RA). It is a dynamic response that expands before the onset of disease and generates antibodies (anti-citrullinated protein antibodies (ACPAs)) that are extensively glycosylated in the variable domain. This feature of ACPAs is remarkable and warrants detailed investigation, as it can offer insights into the earliest immunologic mechanisms that lead up to the development of RA. The acquisition of variable domain glycans, in fact, could enable ACPA-expressing B cells to breach tolerance...
March 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29680162/baseline-patient-reported-outcomes-are-more-consistent-predictors-of-long-term-functional-disability-than-laboratory-imaging-or-joint-count-data-in-patients-with-early-inflammatory-arthritis-a-systematic-review
#3
REVIEW
James M Gwinnutt, Charlotte A Sharp, Deborah P M Symmons, Mark Lunt, Suzanne M M Verstappen
OBJECTIVE: To assess baseline predictors of long-term functional disability in patients with inflammatory arthritis (IA). METHODS: We conducted a systematic review of the literature from 1990 to 2017 using MEDLINE and EMBASE. Studies were included if (i) they were prospective observational studies, (ii) all patients had IA with symptom duration ≤2 years at baseline, (iii) follow-up was at least 5 years, and (iv) baseline predictors of HAQ score at long-term follow-up (i...
March 15, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29799667/subsequent-cardiovascular-events-among-patients-with-rheumatoid-arthritis-psoriatic-arthritis-or-psoriasis-patterns-of-disease-modifying-antirheumatic-drug-treatment
#4
Jeffrey A Sparks, Tamara Lesperance, Neil A Accortt, Daniel H Solomon
OBJECTIVES: To examine disease-modifying antirheumatic drug (DMARD) treatments and estimate risk of a subsequent cardiovascular (CV) event following an initial CV event in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or psoriasis (PsO). METHODS: We analyzed data from MarketScan® claims databases (1/1/2006-6/30/2015) for adults with RA, PsA, or PsO and initial/index CV event (acute myocardial infarction, stroke, or coronary revascularization) while receiving DMARDs (tumor necrosis factor inhibitor [TNFi] biologic DMARDs [bDMARDs], conventional synthetic DMARDs [csDMARDs], or non-TNFi bDMARDs)...
May 25, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/29853455/tocilizumab-discontinuation-after-attaining-remission-in-patients-with-rheumatoid-arthritis-who-were-treated-with-tocilizumab-alone-or-in-combination-with-methotrexate-results-from-a-prospective-randomised-controlled-study-the-second-year-of-the-surprise-study
#5
Yuko Kaneko, Masaru Kato, Yoshiya Tanaka, Masayuki Inoo, Hitomi Kobayashi-Haraoka, Koichi Amano, Masayuki Miyata, Yohko Murakawa, Hidekara Yasuoka, Shintaro Hirata, Eiichi Tanaka, Nobuyuki Miyasaka, Hisashi Yamanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi
OBJECTIVE: To evaluate the sustained remission and low disease activity after discontinuation of tocilizumab in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate. METHODS: The SURPRISE study was a 2-year, open-label randomised controlled study. Among patients who had been randomised to additional tocilizumab (ADD-ON) or switch to tocilizumab (SWITCH) in the first year, those who achieved remission based on the disease activity score for 28 joints (DAS28-ESR<2...
May 31, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29806092/the-lung-in-rheumatoid-arthritis-focus-on-interstitial-lung-disease
#6
REVIEW
Paolo Spagnolo, Joyce C Lee, Nicola Sverzellati, Giulio Rossi, Vincent Cottin
Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid arthritis (RA) and is associated with significant morbidity and mortality. In addition, approximately one-third of patients have subclinical disease with varying degrees of functional impairment. While risk factors for RA-ILD are well established (e.g., older age, male gender, ever smoking history and seropositivity to rheumatoid factor and anti-cyclic citrullinated peptide antibodies) little is known about optimal disease assessment, treatment and monitoring, particularly in patients with progressive disease...
May 27, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29611086/resveratrol-as-an-effective-adjuvant-therapy-in-the-management-of-rheumatoid-arthritis-a-clinical-study
#7
Hani M Khojah, Sameh Ahmed, Mahran S Abdel-Rahman, Eman H Elhakeim
Resveratrol (RSV), a naturally occurring polyphenol, has been found to have potent antioxidant, anti-inflammatory, and anticancer effects. Recently, RSV was reported as a new potential agent to suppress inflammation of collagen-induced arthritis in a mouse model. Nevertheless, the clinical benefits of RSV in the management of rheumatoid arthritis (RA) were not studied. This randomized controlled clinical trial aims to shed some light on the therapeutic benefits of RSV in the treatment of RA in patients with different stages of the disease activity...
April 3, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/28865493/high-titers-of-both-rheumatoid-factor-and-anti-ccp-antibodies-at-baseline-in-patients-with-rheumatoid-arthritis-are-associated-with-increased-circulating-baseline-tnf-level-low-drug-levels-and-reduced-clinical-responses-a-post-hoc-analysis-of-the-rising-study
#8
RANDOMIZED CONTROLLED TRIAL
Tsutomu Takeuchi, Nobuyuki Miyasaka, Takashi Inui, Toshiro Yano, Toru Yoshinari, Tohru Abe, Takao Koike
BACKGROUND: Although both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA), the impact of these autoantibodies on the efficacy of tumor necrosis factor (TNF) inhibitors has been controversial. The aim of this post hoc analysis of a randomized double-blind study (the RISING study) was to investigate the influences of RF and anti-CCP on the clinical response to infliximab in patients with RA. METHODS: Methotrexate-refractory patients with RA received 3 mg/kg of infliximab from weeks 0 to 6 and then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46...
September 2, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28724365/leflunomide-is-equally-efficacious-and-safe-compared-to-low-dose-rituximab-in-refractory-rheumatoid-arthritis-given-in-combination-with-methotrexate-results-from-a-randomized-double-blind-controlled-clinical-trial
#9
RANDOMIZED CONTROLLED TRIAL
Harindu Wijesinghe, Priyadharshini Galappatthy, Rajiva de Silva, Suranjith L Seneviratne, Ushagowry Saravanamuttu, Preethi Udagama, Melanie Hart, Peter Kelleher, Upul Senerath, Rohini Fernandopulle, Lilani P Weerasekera, Lalith S Wijayaratne
BACKGROUND: The standard dose of rituximab used in rheumatoid arthritis (RA) is 1000 mg but recent studies have shown that low dose (500 mg) is also effective. Efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic Disease Modifying Anti Rheumatic Drugs (DMARDs), compared to leflunomide is unknown. In a tertiary care referral setting, we conducted a randomized, double blind controlled clinical trial comparing the efficacy and safety of low-dose rituximab-methotrexate combination with leflunomide-methotrexate combination...
July 19, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28845604/herpes-zoster-and-tofacitinib-clinical-outcomes-and-the-risk-of-concomitant-therapy
#10
Kevin L Winthrop, Jeffrey R Curtis, Stephen Lindsey, Yoshiya Tanaka, Kunihiro Yamaoka, Hernan Valdez, Tomohiro Hirose, Chudy I Nduaka, Lisy Wang, Alan M Mendelsohn, Haiyun Fan, Connie Chen, Eustratios Bananis
OBJECTIVE: Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster (HZ), and the risk appears to be increased in patients treated with tofacitinib. The aim of this study was to evaluate whether concomitant treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or glucocorticoids (GCs) contributes to the increased risk of HZ in RA patients treated with tofacitinib. METHODS: HZ cases were identified from the databases of 2 phase I, 9 phase II, 6 phase III, and 2 long-term extension studies of tofacitinib in RA patients...
October 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28399940/baseline-jak-phosphorylation-profile-of-peripheral-blood-leukocytes-studied-by-whole-blood-phosphospecific-flow-cytometry-is-associated-with-1-year-treatment-response-in-early-rheumatoid-arthritis
#11
Krista Kuuliala, Antti Kuuliala, Riitta Koivuniemi, Hannu Kautiainen, Heikki Repo, Marjatta Leirisalo-Repo
BACKGROUND: We found recently that baseline signal transducer and activator of transcription 3 phosphorylation in peripheral blood CD4+ T cells of patients with early rheumatoid arthritis (RA) is associated with treatment response to synthetic disease-modifying antirheumatic drugs (DMARDs). This prompted us to study the baseline phosphorylation profiles of Janus kinases (JAKs) in blood leukocytes with respect to treatment response in early RA. METHODS: Thirty-five DMARD-naïve patients with early RA provided blood samples for whole blood flow cytometric determination of phosphorylation of JAKs in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes...
April 11, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28598787/severe-adverse-drug-reactions-to-biological-disease-modifying-anti-rheumatic-drugs-in-elderly-patients-with-rheumatoid-arthritis-in-clinical-practice
#12
Leticia Leon, Alejandro Gomez, Cristina Vadillo, Esperanza Pato, Luis Rodriguez-Rodriguez, Juan Angel Jover, Lydia Abasolo
OBJECTIVES: Biological DMARDs are widely used in the treatment of rheumatoid arthritis (RA) but their relationship with adverse drug reaction (ADR) is important. RA is now known to increase in incidence and prevalence with age. Our objective was to assess the incidence of severe ADR in the long term, compare safety between the different bDMARDs and identify other possible risk factors for severe ADR in elderly RA patients. METHODS: A 14-year retrospective longitudinal study was performed...
January 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28473424/glucocorticoids-in-rheumatoid-arthritis-the-picture-is-shaping-up
#13
EDITORIAL
Frank Buttgereit, Johannes W Bijlsma
No abstract text is available yet for this article.
November 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28215362/efficacy-and-safety-of-sirukumab-in-patients-with-active-rheumatoid-arthritis-refractory-to-anti-tnf-therapy-sirround-t-a-randomised-double-blind-placebo-controlled-parallel-group-multinational-phase-3-study
#14
RANDOMIZED CONTROLLED TRIAL
Daniel Aletaha, Clifton O Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul P Tak, Sharon Popik
BACKGROUND: Sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, is under development for the treatment of rheumatoid arthritis and other diseases. We aimed to assess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T). METHODS: We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre study at 183 hospitals and private rheumatology clinics in 20 countries (Argentina, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Taiwan, UK, and USA)...
March 25, 2017: Lancet
https://www.readbyqxmd.com/read/28356243/efficacy-of-glucocorticoids-conventional-and-targeted-synthetic-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#15
REVIEW
Katerina Chatzidionysiou, Sharzad Emamikia, Jackie Nam, Sofia Ramiro, Josef Smolen, Désirée van der Heijde, Maxime Dougados, Johannes Bijlsma, Gerd Burmester, Marieke Scholte, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To perform a systematic literature review (SLR) informing the 2016 update of the recommendations for the management of rheumatoid arthritis (RA). METHODS: An SLR for the period between 2013 and 2016 was undertaken to assess the efficacy of glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and targeted synthetic DMARDs (tsDMARDs) (tofacitinib and baricitinib) in randomised clinical trials. RESULTS: For GCs, four studies were included in the SLR...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28298374/safety-of-synthetic-and-biological-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-management-of-rheumatoid-arthritis
#16
REVIEW
Sofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, Jackie L Nam, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Johannes W Bijlsma, Gerd R Burmester, Marieke Scholte-Voshaar, Louise Falzon, Robert B M Landewé
OBJECTIVES: To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. METHODS: Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#17
REVIEW
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28367663/three-out-of-four-disease-modifying-anti-rheumatic-drug-na%C3%A3-ve-rheumatoid-arthritis-patients-meet-28-joint-disease-activity-score-remission-at-12-months-results-from-the-fin-era-cohort
#18
T Rannio, J Asikainen, P Hannonen, T Yli-Kerttula, P Ekman, L Pirilä, L Kuusalo, M Mali, M Puurtinen-Vilkki, S Kortelainen, J Paltta, K Taimen, M Kauppi, K Laiho, S Nyrhinen, H Mäkinen, P Isomäki, T Uotila, K Aaltonen, H Kautiainen, T Sokka
OBJECTIVE: To assess what proportion of patients with disease-modifying anti-rheumatic drug (DMARD)-naïve early rheumatoid arthritis (ERA) reach 28-joint Disease Activity Score (DAS28) remission over 1 year, and remission variability across clinics in Finland. METHOD: Patients with DMARD-naïve newly diagnosed inflammatory arthritis were recruited. The proportion of patients in 28-joint Disease Activity Score with three variables (DAS28-3) remission was compared across sites...
November 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/23104761/smoking-and-overweight-determine-the-likelihood-of-developing-rheumatoid-arthritis
#19
MULTICENTER STUDY
Maria J H de Hair, Robert B M Landewé, Marleen G H van de Sande, Dirkjan van Schaardenburg, Lisa G M van Baarsen, Danielle M Gerlag, Paul P Tak
OBJECTIVES: Rheumatoid arthritis (RA) is a prototypic chronic inflammatory disease with a debilitating course if untreated. A genetic predisposition for RA is known, and its occurrence is associated with the presence of autoantibodies in the serum and with environmental factors. It is unknown if smoking and overweight are contributory factors for developing RA in individuals with RA-specific autoantibodies in the serum. METHODS: Fifty-five individuals at risk for developing RA, based on the presence of RA-specific autoantibodies in the serum, who never had any evidence of arthritis upon physical examination, were followed over time...
October 2013: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/24934191/defining-populations-at-risk-of-rheumatoid-arthritis-the-first-steps-to-prevention
#20
REVIEW
Laura Hunt, Paul Emery
Preventing disease is a public health priority. In recent years, this focus has evolved to include noncommunicable chronic diseases such as cardiovascular disease and diabetes mellitus but is novel in rheumatic diseases such as rheumatoid arthritis (RA). In order to prevent RA, the 'at-risk' populations need to be defined. To date, a number of studies have attempted to clarify our understanding of these cohorts and how they could be identified. Suggested terminology has now been published to define individuals who might go on to develop RA...
September 2014: Nature Reviews. Rheumatology
label_collection
label_collection
5160
1
2
2017-03-25 18:02:52
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"